

Oronzo Brunetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5752805/publications.pdf>

Version: 2024-02-01

109
papers

2,775
citations

172457

29
h-index

254184

43
g-index

123
all docs

123
docs citations

123
times ranked

4559
citing authors

#	ARTICLE	IF	CITATIONS
1	Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. <i>Clinical and Experimental Medicine</i> , 2022, 22, 65-74.	3.6	41
2	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , 2022, 34, 123-132.	1.5	1
3	Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112370.	5.6	10
4	Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112558.	5.6	10
5	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112516.	5.6	38
6	The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112588.	5.6	14
7	Evolving pancreatic cancer treatment: From diagnosis to healthcare management. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103571.	4.4	17
8	Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112691.	5.6	7
9	Identification of Common and Distinct Pathways in Inflammatory Bowel Disease and Colorectal Cancer: A Hypothesis Based on Weighted Gene Co-Expression Network Analysis. <i>Frontiers in Genetics</i> , 2022, 13, 848646.	2.3	6
10	The regulatory role of autophagy-related miRNAs in lung cancer drug resistance. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112735.	5.6	26
11	The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103674.	4.4	17
12	Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. <i>Molecules</i> , 2022, 27, 3545.	3.8	1
13	Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. <i>Human Pathology</i> , 2022, 128, 124-133.	2.0	6
14	Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients. <i>Oncology</i> , 2021, 99, 292-299.	1.9	6
15	COVID Vaccination in Cancer Patients: What Vaccination Priority Strategies Should There Be?. <i>Frontiers in Oncology</i> , 2021, 11, 641388.	2.8	10
16	Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?. <i>Medical Oncology</i> , 2021, 38, 17.	2.5	2
17	Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1906.	3.7	6
18	The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. <i>Frontiers in Immunology</i> , 2021, 12, 676181.	4.8	32

#	ARTICLE	IF	CITATIONS
19	Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine. <i>Cancers</i> , 2021, 13, 2414.	3.7	58
20	The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111364.	5.6	21
21	A Systematic Review to Clarify the Prognostic Values of CD44 and CD44+CD24- Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The Road Ahead. <i>Frontiers in Oncology</i> , 2021, 11, 689839.	2.8	9
22	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , 2021, 9, 1075.	3.2	46
23	A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery. <i>Genes</i> , 2021, 12, 1206.	2.4	35
24	A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology. <i>Frontiers in Immunology</i> , 2021, 12, 734956.	4.8	4
25	A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10389.	4.1	14
26	Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. <i>Life Sciences</i> , 2021, 282, 119826.	4.3	25
27	A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112213.	5.6	21
28	Hepatocellular Cancer. <i>UNIPA Springer Series</i> , 2021, , 689-706.	0.1	2
29	The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10719.	4.1	36
30	Cholangiocarcinoma: new perspectives for new horizons. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1367-1383.	3.0	13
31	PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 1007-1016.	3.4	13
32	Photodynamic Therapy with Zinc Phthalocyanine Inhibits the Stemness and Development of Colorectal Cancer: Time to Overcome the Challenging Barriers?. <i>Molecules</i> , 2021, 26, 6877.	3.8	6
33	A Promising Role of TGF- β 2 Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 1241.	2.0	3
34	A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 788211.	4.8	5
35	Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. <i>Life</i> , 2021, 11, 1355.	2.4	8
36	Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma?. <i>Pancreas</i> , 2020, 49, e11-e11.	1.1	0

#	ARTICLE	IF	CITATIONS
37	NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1587.	2.8	19
38	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 773-785.	3.6	12
39	The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5034.	4.1	30
40	Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8305.	4.1	58
41	Targeting TGF- β -Mediated SMAD Signaling Pathway via Novel Recombinant Cytotoxin II: A Potent Protein from <i>Naja naja oxiana</i> Venom in Melanoma. <i>Molecules</i> , 2020, 25, 5148.	3.8	10
42	Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-7.	1.9	1
43	Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. <i>Frontiers in Oncology</i> , 2020, 10, 572329.	2.8	7
44	On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents. <i>Frontiers in Oncology</i> , 2020, 10, 1340.	2.8	3
45	Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection. <i>Frontiers in Oncology</i> , 2020, 10, 1292.	2.8	2
46	MicroRNAs and lncRNAs—A New Layer of Myeloid-Derived Suppressor Cells Regulation. <i>Frontiers in Immunology</i> , 2020, 11, 572323.	4.8	17
47	Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1594.	2.4	49
48	Expression and characterization of a novel recombinant cytotoxin II from <i>Naja naja oxiana</i> venom: A potential treatment for breast cancer. <i>International Journal of Biological Macromolecules</i> , 2020, 162, 1283-1292.	7.5	5
49	Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). <i>Cancers</i> , 2020, 12, 1681.	3.7	20
50	Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. <i>Cancers</i> , 2020, 12, 1729.	3.7	26
51	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4427.	4.1	67
52	Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2020, 12, 534.	3.7	15
53	Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 275.	3.7	50
54	MIR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2578.	4.1	35

#	ARTICLE	IF	CITATIONS
55	COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?. <i>Frontiers in Oncology</i> , 2020, 10, 734.	2.8	38
56	Immune system and bone microenvironment: rationale for targeted cancer therapies. <i>Oncotarget</i> , 2020, 11, 480-487.	1.8	45
57	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. <i>Cancers</i> , 2019, 11, 942.	3.7	66
58	Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Medicina (Lithuania)</i> , 2019, 55, 698.	2.0	54
59	Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1972-1976.	0.5	12
60	Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 1718.	3.7	27
61	Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. <i>Medicina (Lithuania)</i> , 2019, 55, 707.	2.0	53
62	Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. <i>Cancers</i> , 2019, 11, 1270.	3.7	25
63	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. <i>Cancers</i> , 2019, 11, 749.	3.7	4
64	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Società Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 39-51.	4.4	11
65	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. <i>Cancers</i> , 2019, 11, 539.	3.7	45
66	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	2.8	36
67	CAFs and TGF- β 2 Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 330.	3.7	71
68	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	1.1	7
69	Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13087.	3.4	33
70	Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2379-2383.	0.5	7
71	Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies. <i>Medicina (Lithuania)</i> , 2019, 55, 754.	2.0	55
72	Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. <i>Clinical and Experimental Medicine</i> , 2018, 18, 319-323.	3.6	30

#	ARTICLE	IF	CITATIONS
73	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018, 12, 33-37.	2.4	5
74	Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 453-461.	3.4	15
75	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	1.1	14
76	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771.	1.1	29
77	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. <i>Scientific Reports</i> , 2017, 7, 42499.	3.3	30
78	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 152-165.	4.4	28
79	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 1-12.	4.4	26
80	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	2.8	11
81	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 709-721.	3.1	85
82	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017, 13, 2265-2275.	2.4	10
83	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. <i>European Journal of Cancer</i> , 2017, 86, 106-114.	2.8	76
84	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 795-803.	3.6	23
85	Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). <i>ESMO Open</i> , 2017, 2, e000167.	4.5	27
86	Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. <i>Annals of Oncology</i> , 2017, 28, iii1-iii2.	1.2	2
87	Immunotherapeutic approaches for hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 33897-33910.	1.8	50
88	Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. <i>International Journal of Molecular Sciences</i> , 2017, 18, 418.	4.1	47
89	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. <i>Oncotarget</i> , 2017, 8, 66699-66708.	1.8	11
90	Angiogenesis in adenosquamous cancer of pancreas. <i>Oncotarget</i> , 2017, 8, 95773-95779.	1.8	19

#	ARTICLE	IF	CITATIONS
91	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4681-4686.	2.0	9
92	Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. <i>Oncotarget</i> , 2016, 7, 58649-58658.	1.8	76
93	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. <i>Targeted Oncology</i> , 2016, 11, 593-603.	3.6	14
94	The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. <i>Scientific Reports</i> , 2016, 6, 24136.	3.3	22
95	Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. <i>Cancer Biology and Therapy</i> , 2016, 17, 400-406.	3.4	67
96	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 309-324.	4.4	35
97	Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6287.	3.3	8
98	Innovative surgical approaches for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2016, 8, 591.	2.0	21
99	Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. <i>BMC Cancer</i> , 2015, 15, 692.	2.6	16
100	MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. <i>Oncotarget</i> , 2015, 6, 23323-23341.	1.8	65
101	Paraneoplastic Focal Segmental Glomerulosclerosis in Sarcomatoid Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, e66-e70.	1.6	5
102	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 1140-1147.	3.4	12
103	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2719-2725.	1.8	66
104	Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1623-1635.	3.4	58
105	Bone metastases in hepatocellular carcinoma: an emerging issue. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 333-342.	5.9	38
106	Novel lenalidomide-based combinations for treatment of multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 9-20.	4.4	11
107	Therapeutic approaches to myeloma bone disease: An evolving story. <i>Cancer Treatment Reviews</i> , 2012, 38, 787-797.	7.7	25
108	<i>In vitro</i> anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. <i>British Journal of Haematology</i> , 2012, 157, 586-598.	2.5	46

#	ARTICLE	IF	CITATIONS
109	Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation inÂvitro. <i>Experimental Hematology</i> , 2011, 39, 773-783.e1.	0.4	33